188 related articles for article (PubMed ID: 33138869)
1. Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective.
Hillock NT; Merlin TL; Karnon J; Turnidge J; Eliott J
Int J Technol Assess Health Care; 2020 Nov; 37():e28. PubMed ID: 33138869
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study.
Hillock NT; Merlin TL; Karnon J; Turnidge J; Eliott J
JAC Antimicrob Resist; 2020 Jun; 2(2):dlaa023. PubMed ID: 34222987
[TBL] [Abstract][Full Text] [Related]
3. Health technology assessment. The pharmaceutical industry perspective.
Schubert F
Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment of medicines in Greece: pharmaceutical industry executives' views.
Armataki E; Karampli E; Kyriopoulos J; Pavi E
Int J Technol Assess Health Care; 2014 Apr; 30(2):226-32. PubMed ID: 24806287
[TBL] [Abstract][Full Text] [Related]
5. Value added medicines: what value repurposed medicines might bring to society?
Toumi M; Rémuzat C
J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
[No Abstract] [Full Text] [Related]
6. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
[TBL] [Abstract][Full Text] [Related]
7. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
8. STAKEHOLDER INVOLVEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN LATIN AMERICA.
Pichon-Riviere A; Soto N; Augustovski F; Sampietro-Colom L
Int J Technol Assess Health Care; 2018 Jan; 34(3):248-253. PubMed ID: 29888698
[TBL] [Abstract][Full Text] [Related]
9. Essential Medicines in a High Income Country: Essential to Whom?
Duong M; Moles RJ; Chaar B; Chen TF;
PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544
[TBL] [Abstract][Full Text] [Related]
10. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
11. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
12. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
13. Defining the Value of Health Technologies in Latin America: Developments in Value Frameworks to Inform the Allocation of Healthcare Resources.
Pichon-Riviere A; Garcia-Marti S; Oortwijn W; Augustovski F; Sampietro-Colom L
Int J Technol Assess Health Care; 2019 Jan; 35(1):64-68. PubMed ID: 30938278
[TBL] [Abstract][Full Text] [Related]
14. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
15. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
16. Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patients.
Hillock NT; Paradiso L; Turnidge J; Karnon J; Merlin TL
Aust Health Rev; 2020 Apr; 44(2):263-269. PubMed ID: 31272525
[TBL] [Abstract][Full Text] [Related]
17. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
18. Early dialogue with health technology assessment bodies: a European perspective.
Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
[TBL] [Abstract][Full Text] [Related]
19. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
20. Patient advocacy group involvement in health technology assessments: an observational study.
Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
